HER2 testing Market Analysis

Cancer Type (Breast Cancer, Gastric Cancer, Bladder Cancer, Ovarian Cancer)

Based on cancer type, the breast cancer segment in the HER2 testing market is anticipated to hold the largest revenue share of about 40% during the forecast period. Throughout the projection period, breast cancer is anticipated to have the greatest growth rate in the HER 2 testing market. The risk factors that raise the incidence of breast cancer include aging, genetic mutations, reproductive history, having thick breasts, having a personal or family history of the disease, and drug exposure. HER3 genes change and produce additional copies of themselves in breast cancer. The purpose of HER2 testing is to determine whether the cancer is HER-2 positive and to determine whether the malignancy is responding to treatment or coming back after it has been stopped. In 2020, 685,000 people died worldwide from breast cancer, accounting for 2.3 million new diagnoses. Breast cancer is the most common cancer worldwide, with 7.8 million people surviving as of the end of 2020 who received a diagnosis within the previous five years.

End Users (Hospital, Diagnostic Centers, Specialty Clinics)

Based on end users, the hospital segment in the HER2 testing market is attributed to hold the largest revenue share of about 48% during the forecast period. This test was primarily used by clinicians in hospitals to identify tumors with higher-than-normal amounts of the HER2 protein or cancer cells with an excessive number of HER2 gene copies. Hospital laboratories examine a sample of breast cancer tissue retrieved during surgery or biopsy for HER2 levels in invasive breast tumors. Rather than diagnostic labs, the hospitals are equipped with state-of-the-art medical technology. Hospitals may readily obtain Fluorescence in Situ Hybridization (FISH) devices, which are a prerequisite for the HER 2 test. Therefore, the market for HER 2 testing is dominated by hospitals.

Our in-depth analysis of the global HER2 testing market includes the following segments:

Technique	Immunohistochemistry (IHC) Test Fluorescence in Situ Hybridization Chromogenic in Situ Hybridization Silver-Enhanced in Situ Hybridization
Cancer Type	Breast Cancer Gastric Cancer Bladder Cancer Ovarian Cancer
End Users	Hospital Diagnostic Centers Specialty Clinics

Frequently Asked Questions (FAQ)

Increasing research and development in cancer diagnostic technologies and the popularity of HER2 testing for breast cancer screening are the major factors driving the growth of the HER2 testing market.

The market size of HER2 testing is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Thermo Fisher Scientific, Roche, Empire Genomics Inc., Abnova Corporation, Eli Lilly and Company, Oxford Gene Technology IP Limited, Genetech, Genemed Technologies Inc., PERKINELMER Inc., and others.

The breast cancer segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

HER2 testing Market Analysis